Clinical Trial Update: Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine and split-dose cisplatin plus sorafenib in chemotherapy-naïve urothelial carcinoma of the bladder. The study was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Gemzar (gemcitabine)
• Nexavar (Sorafenib)
• Platinol (cisplatin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer, URINARY BLADDER | Phase 2 | Status: TERMINATED | Results posted: 2015-11-16